Dataset: 11.1K articles from the COVID-19 Open Research Dataset (PMC Open Access subset)
All articles are made available under a Creative Commons or similar license. Specific licensing information for individual articles can be found in the PMC source and CORD-19 metadata
.
More datasets: Wikipedia | CORD-19

Logo Beuth University of Applied Sciences Berlin

Made by DATEXIS (Data Science and Text-based Information Systems) at Beuth University of Applied Sciences Berlin

Deep Learning Technology: Sebastian Arnold, Betty van Aken, Paul Grundmann, Felix A. Gers and Alexander Löser. Learning Contextualized Document Representations for Healthcare Answer Retrieval. The Web Conference 2020 (WWW'20)

Funded by The Federal Ministry for Economic Affairs and Energy; Grant: 01MD19013D, Smart-MD Project, Digital Technologies

Imprint / Contact

Highlight for Query ‹Circovirus Infection of birds symptoms

Enforced microglial depletion and repopulation as a promising strategy for the treatment of neurological disorders

INTRODUCTION

Microglia are highly specialized and dynamic cellular components of the central nervous system (CNS) originating from embryonic precursors in the yolk sac, comprising approximately 10% of the total glial cell number in the adult brain (Ginhoux et al., 2010; Labzin, Heneka, & Latz, 2017; Li & Barres, 2017). Microglia have traditionally been considered to be in a resting and quiescent state in physiological conditions. With the advent of elegant two/multiple photon microscopy image techniques, genetic and molecular targeting tools, we now appreciate that in normal conditions microglia have a ramified morphology, are maintained by diverse signals from neurons and can continuously move their dendrites, which allows for constant active screening of the surrounding microenvironment (Kierdorf & Prinz, 2017; Nimmerjahn, Kirchhoff, & Helmchen, 2005).

Microglia are long‐lived cells with a relatively low turnover. By genetically labeling microglia in pathogen‐free mice it was recently determined that microglia can survive during the whole lifespan of an animal, and can thus exert crucial long‐lasting influences on neurodegenerative disorders (Fuger et al., 2017). However, it is well documented that microglia can be self‐regulated without contribution from peripheral myeloid cells and their turnover is tightly controlled by the coupling of apoptosis, with approximately 1% murine microglia dying in 1 day and the whole population of cells renewing several times throughout life (Askew et al., 2017; Tay et al., 2017). Although significant species differences in microglial biology such as microglial density were noted, this finding also concords with observations in humans, a recent study highlighting that more than 96% of human microglia can be slowly renewed throughout life (Reu et al., 2017).

Microglial cells are believed to play multifunctional roles in both inflammatory and physiological contexts (Grabert et al., 2016; Thompson & Tsirka, 2017). In the healthy brain microglia efficiently monitor CNS homeostasis and have a marked impact on neural development. In order to actively survey the CNS they have recently been demonstrated to require the proper activity of tandem‐pore domain halothane‐inhibited K+ channel 1, which is the main K+ channel expressed in microglial cells (Madry et al., 2017). In several pathological conditions such as epilepsy, single‐cell RNA sequencing of hippocampal microglia indicated that microglia undergo dramatically transcriptomic alterations (more than 2,000 differentially expressed genes) and immunological activation during early time points, particularly regarding mitochondrial activity and metabolic pathways (Bosco et al., 2018). As such they play an indispensable role in the inflammatory cascade. Some studies based on comprehensive single cell RNA sequencing experiments have reported that microglia do not vary considerably in the whole brain (Keren‐Shaul et al., 2017; Matcovitch‐Natan et al., 2016). However, a recent study provides further novel evidence that CD11b+ microglia in the circumventricular regions are actually maintained in the activated state even during physiological conditions (Takagi, Furube, Nakano, Morita, & Miyata, 2017). Microglia in this specific region not only display the amoeboid morphology rather than the ramified form, but also express high protein levels of activation markers in the healthy mouse brain (Takagi et al., 2017).

This recent report is consistent with the view that while microglia are uniformly distributed throughout the CNS they appear to perform characteristic functions in specific regions (De Biase et al., 2017; Marshall, Deleyrolle, Reynolds, Steindler, & Laywell, 2014). Indeed, genome‐wide transcriptional studies have reported that the bio‐energetic and immunoregulatory functions of microglia varied considerably in different anatomical regions, evidenced by cerebellar and cortical microglia displaying distinct gene expression profiles under steady‐state conditions (Grabert et al., 2016). More specifically, a recent study provides convincing evidence of an epigenetic mechanism involved in the clearance activity of microglia that differs regionally in the adult brain (Ayata et al., 2018). Variations in microglial profiles may also depend on the specific diseases states (Mastroeni et al., 2017), significantly altered transcripts having been reported in the hippocampus of Alzheimer's disease (AD) and in the substantia nigra of Parkinson's disease (PD), respectively (Mastroeni et al., 2017).

It is now well accepted that alterations in microglial activity and dysregulated microglial‐induced neuroinflammation have dual effects on many neurological diseases (Du et al., 2017; Salter & Stevens, 2017). Although the microglial field is intensively researched at present, less is still known about how microglia can be precisely targeted for optimal therapeutic efficacy. The concept of glial replacement therapy using progenitors has recently been proposed (Cartier, Lewis, Zhang, & Rossi, 2014; Shen, Li, Bao, & Wang, 2017; Srivastava, Bulte, Walczak, & Janowski, 2017). In this review we will introduce and discuss a new experimental paradigm to specifically control the excessive activation of microglia in vivo using fully differentiated and pre‐activated cells, and provide a rationale for its translation into clinical practice.

MULTI‐TASKING MICROGLIA: A FRIEND FOR BRAIN HOMEOSTASIS

Microglia can perform diverse functions to maintain overall tissue integrity during steady‐state conditions (Colonna & Butovsky, 2017; Kabba et al., 2017; Mosser, Baptista, Arnoux, & Audinat, 2017; Prinz, Erny, & Hagemeyer, 2017). Indeed, a growing body of evidence convincingly demonstrates that microglia are recognized for acting as “busy bees” and maintain an expanding array of functions during both early brain development and adult homeostasis (Figure 1). In particular, microglia can secrete a broad range of protective neurotrophic substances such as brain‐derived neurotrophic factor (BDNF), vascular endothelial growth factor, neuronal growth factor (NGF), insulin‐like growth factor‐1 (IGF‐1), platelet‐derived growth factors and transforming growth factor‐β (TGF‐β) (Butovsky et al., 2014; Parkhurst et al., 2013; Shibata & Suzuki, 2017; Wlodarczyk et al., 2017), thus ensuring appropriate neuronal network development and maintenance as well as enhancing memory and learning (Molteni & Rossetti, 2017; Parkhurst et al., 2013). There is a widespread consensus that microglia are also in active intimate contact with neighboring neuronal and non‐neuronal cells, thereby regulating neuronal proliferation, migration and differentiation and refining the neural circuits (Frost & Schafer, 2016; Mosser et al., 2017).

In order to perform these above‐mentioned functions a diverse array of receptors including TAM receptors, glutamate receptors, and purinergic receptors are used by microglia to efficiently communicate with other cells (Fourgeaud et al., 2016; York, Bernier, & MacVicar, 2017). Among these complex systems the CX3CL1/CX3CR1 and CD200‐CD200R axes play key roles in microglia–neuron contact (Eyo & Wu, 2013; Kierdorf & Prinz, 2017; Limatola & Ransohoff, 2014; Mecca, Giambanco, Donato, & Arcuri, 2018). Indeed, the CX3CR1−/− mouse exhibited profound alterations in both morphology and connectivity of the mature newborn hippocampal granule neurons (Bolos et al., 2017). The CD200−/− mouse exhibits an activated microglial phenotype accompanied by high expression of CD11b and CD45 (Hoek et al., 2000). Concurrently, microglia are critically involved in neural repair through phagocytic scavenging, such as clearing dead tissues, ingesting plaques, and apoptotic cells (Michell‐Robinson et al., 2015).

Furthermore, microglia participate in synaptogenesis by producing neurotrophic substances, such as BDNF, as well as eliminating excessive presynaptic and postsynaptic elements through synaptic pruning via the activation of the complement pathway (Masuda & Prinz, 2016; Sominsky, De Luca, & Spencer, 2017; Stevens et al., 2007; Um, 2017). In addition to the complement‐mediated mechanism, astrocyte‐derived interleukin (IL)‐33 is also physiologically required to maintain synapse homeostasis by modulating microglial synapse engulfment (Vainchtein et al., 2018). Microglia are involved in regulating and shaping both excitatory and inhibitory synapses, such as γ‐aminobutyric acid‐expressing and glycinergic synapses (Cantaut‐Belarif et al., 2017; Um, 2017). Conversely, early evidence obtained from CX3CR1 gene‐deleted mice indicated that reduced numbers of microglial cells during brain development could impair the processes of synaptic pruning, resulting in a significantly higher density of dendritic spines and immature synapses (Paolicelli et al., 2011; Shibata & Suzuki, 2017). During adult neurogenesis, microglia actively contribute to regulate the dynamics, maintenance, and functions of synapses of adult‐born neurons (Reshef et al., 2017).

In addition to their well‐described immunological roles, newly emerging neurobiological functions of microglia are currently being recognized and studied. It has been recently determined that a subpopulation of transiently activated microglia, identified in early postnatal white matter region, can directly contribute to the maintenance of oligodendrocyte progenitor numbers and subsequent myelinogenesis in the mouse, since a decreased oligodendrocyte progenitor number was noted following injection of the selective colony‐stimulating factor 1 receptor (CSF‐1R) inhibitor BLZ945 that effectively depletes microglia (Hagemeyer et al., 2017). Other recent observations provide evidence that microglia actively regulate neurovascular homeostasis, such as forming new blood vessels and the vascular branching of the retina and hindbrain (Arcuri, Mecca, Bianchi, Giambanco, & Donato, 2017; Brandenburg et al., 2016; Dudvarski Stankovic, Teodorczyk, Ploen, Zipp, & Schmidt, 2016; Zhao, Eyo, Murugan, & Wu, 2018). In a historical perspective remarkable progress has been made in deciphering many aspects of microglial biology. Further in vivo studies are still warranted to characterize and explore the versatile features of microglia.

THE ROLE OF MICROGLIA IN NEUROLOGICAL DISEASES: FRIEND OR FOE?

Apart from beneficial roles in the development of CNS, microglia can be widely involved in various types of neurological disorders, including stroke (Guruswamy & ElAli, 2017; Kronenberg et al., 2017), multiple sclerosis (MS) (Bogie, Stinissen, & Hendriks, 2014; Luo et al., 2017), AD (Hansen, Hanson, & Sheng, 2017; Sarlus & Heneka, 2017), PD (Subramaniam & Federoff, 2017), sleep disorders (Nadjar, Wigren, & Tremblay, 2017), amyotrophic lateral sclerosis (ALS) (Geloso et al., 2017; Liu & Wang, 2017), Huntington's disease (H. M. Yang, Yang, Huang, Tang, & Guo, 2017), epilepsy (Eyo, Murugan, & Wu, 2017; Zhao, Liao, et al., 2018), gliomas (Hambardzumyan, Gutmann, & Kettenmann, 2016; Schiffer, Mellai, Bovio, & Annovazzi, 2017), Prion diseases (Aguzzi & Zhu, 2017; Obst, Simon, Mancuso, & Gomez‐Nicola, 2017), psychiatric disorders (Mondelli, Vernon, Turkheimer, Dazzan, & Pariante, 2017; Prinz & Priller, 2014; Setiawan et al., 2018; Singhal & Baune, 2017), neuropathic pain (Inoue & Tsuda, 2018; Peng et al., 2016), adrenomyeloneuropathy (Gong et al., 2017), and traumatic brain injury (Donat, Scott, Gentleman, & Sastre, 2017). In general, microglia can be rapidly activated depending upon different stimulatory contexts and environmental changes through diverse molecular and cellular programs, subsequently transforming into the activated state and enhancing the expression of the Toll‐like receptors which sensitively bind microbial structures (Arcuri et al., 2017).

In addition to these morphological changes, activated microglia can acquire an altered gene expression pattern toward functionally distinct phenotypes. Once provoked, microglia produce pro‐inflammatory cytokines and chemokines, such as IL‐1, IL‐6, IL‐23, interferon gamma‐γ (IFN‐γ), CC chemokine ligand 2 (CCL2) and tumor necrosis factor‐α (TNF‐α) (Natoli et al., 2017; Nicolas et al., 2017; Smith, Das, Ray, & Banik, 2012), which are toxic to neighboring neurons and other glial cells such as astrocytes and oligodendrocytes. Nevertheless, activated microglia are more than simply destructive, it being widely recognized that immunoregulatory microglia are required for regulating brain repair and regeneration by secreting anti‐inflammatory factors, such as IL‐4, IL‐10, IL‐13, and TGF‐β (Cherry, Olschowka, & O'Banion, 2014; X. Jin & Yamashita, 2016).

Despite that microglia are necessary for repairing the CNS in normal conditions, activated microglia suppress the processes of brain repair by inhibiting the differentiation of oligodendrocyte precursor cells into myelinating oligodendrocytes via distinct mechanisms including heat shock protein 60 production, NO‐dependent oxidative damage and TNF‐α signaling (Li, Zhang, et al., 2017; Pang et al., 2010). Following pathological alterations, extracellular adenosine triphosphate, a source of energy metabolism, produced by dead and injured neurons can in turn activate microglia via purinergic receptors (Liu & Wang, 2017). Excessive activation of microglia can induce mitochondrial damage and decrease mitochondrial oxygen consumption depending on the degree of their activity, thus influencing total brain energy metabolism and exacerbating disease states (Ghosh, Castillo, Frias, & Swanson, 2017). Activated microglia can also be viewed as a major source of reactive oxidative stress through the release of reactive oxygen species and reactive nitrogen species, which cause oxidative damage to neurons and exacerbate the inflammatory cascade.

Moreover, excessively activated microglia have detrimental effects on neurogenesis, contribute to neuronal death and aggravate long‐term neurological deficits by hindering axonal regeneration (Kitayama, Ueno, Itakura, & Yamashita, 2011; Papageorgiou et al., 2016; Rodriguez et al., 2017). In vivo, microglia may even have a functional interaction with peripherally derived immune cells in the circulation in healthy subjects (Kanegawa et al., 2016). A recent exciting study has reported that activation of microglia plays a central role in inducing neurotoxic reactive astrocytes through production of IL‐1α, TNF, and C1q. The reactive astrocytes induced by activated microglia, termed A1, lose their homeostatic functions and consequently contribute to the death of neurons and differentiated oligodendrocytes (Liddelow et al., 2017). In addition, activated microglia have been shown to inhibit anti‐inflammatory TGF‐β signaling by downregulating TGF‐β‐regulated gene expression and this prolongs chronic microglial dysfunction, partly through the NF‐κB signaling pathway (Affram, Mitchell, & Symes, 2017). In this way microglial cells may prevent a return to normal homeostatic function. Conversely, if chronic inflammation mediated by persistent dysfunction of microglia remains after injury, this could lead to further extensive tissue damage, neuronal loss and cognitive deficits (Donat et al., 2017). In summary, although microglia are essential for the development and normal function of the CNS, dysregulated microglia contribute to disease severity in various neurological pathologies.

SUBSETS OF MICROGLIA: MORE THAN PRO‐INFLAMMATORY AND IMMUNOREGULATORY

Similar to macrophages in the periphery and other organs, microglia exhibit differential activation states generally associated with pro‐inflammatory or immunoregulatory functions (Mecha, Carrillo‐Salinas, Feliu, Mestre, & Guaza, 2016). The former contribute to neuroinflammation and neuronal injury through secretion of pro‐inflammatory and neurotoxic mediators, whereas the latter exert crucial influences on tissue repair through production of anti‐inflammatory cytokines (Tang & Le, 2016). We have argued that it is functional states and not in vitro induced surface marker expression phenotypes that should be used to describe activated myeloid cells (Mills, Harris, & Ley, 2015), and the classification of M1 and M2 functionally polarized states for microglia is now considered less valid (Ransohoff, 2016). Despite this conceptual development, at least nine subgroups of macrophage activation states based on transcriptome‐based network analysis have been proposed (Xue et al., 2014). It has been mostly ignored that novel subpopulations of macrophages such as CD169+ macrophages and T cell receptor positive (TCR+) macrophages may play different roles during specific conditions (Chavez‐Galan, Olleros, Vesin, & Garcia, 2015).

We are beginning to recognize that activated microglia are also quite plastic cells that may differentiate into a plethora of subsets and perform various functions in response to different stimuli and environmental changes such as obesity, diet, alcohol, and even the host microbiota (Chunchai, Chattipakorn, & Chattipakorn, 2017; Erny et al., 2015; Hanamsagar & Bilbo, 2017; Henriques et al., 2017; Johnson, 2015; Mathys et al., 2017; Menzel et al., 2017). In support of this, it has recently been reported that microglia can even respond to microbial challenges during embryogenesis, and that the absent status of a microbiome has a quite different impact on both age‐ and sex‐specific microglial gene expression (Thion et al., 2017). Furthermore, emerging data have indicated that mixed activation states are evident in later active lesions of MS whereby the activated microglia did not express purinergic receptor P2RY12, which is a novel and specific marker for homeostatic microglia (Zrzavy et al., 2017). Microglial cells may also display distinct activation patterns in the setting of AD, recently evidenced by different morphological properties between plaque‐associated and plaque‐distinct microglia using three‐dimensional cell analysis in an AD animal model (Plescher et al., 2018).

Newly emerging phenotypes of microglia continue to be described and investigated. Specifically, the existence of disease‐associated microglia during pathological states, for example in the APP‐PS1 mouse and the CX3CR1 knockout mouse, has been indicated at the ultrastructural level by transmission electron microscopy (Bisht, Sharma, Lecours, et al., 2016). Even though such disease‐associated microglia express microglial markers, such as CD11b, IBA1, and TREM2, this specific subset of cells has been suggested to be strikingly different from normal microglia since they exhibit signs of oxidative stress and transpire to be phagocytically hyperactive with highly ramified processes during pathological states. Such disease‐associated microglia can also cause abnormal interactions with synapses and lead to cognitive decline and learning deficits (Bisht, Sharma, Lacoste, & Tremblay, 2016; Bisht, Sharma, Lecours, et al., 2016). Interestingly, another unique neonatal white matter‐associated CD11c+ microglial subset has been described that specifically contributes to myelination and neurogenesis during postnatal brain development by producing neuroprotective IGF1. Although these repopulating CD11c+ microglia were evident following genetic adult microglial depletion using CX3CR1CreER iDTR mice, the newly repopulated CD11c+ microglia did not exhibit a neurogenic gene expression profile characteristic of the neonatal CD11c+ microglial subset (Bennett & Barres, 2017; Wlodarczyk et al., 2017). Consistently, the same research group also determined that CD11c+ microglia and CD11c− microglia have different roles in the contexts of cuprizone‐induced demyelination, experimental autoimmune encephalomyelitis (EAE) and neuromyelitis optica‐like disease models (Wlodarczyk et al., 2015).

Moreover, another unique type of disease‐associated microglia has been discovered in AD mice (through using massively parallel single‐cell RNA sequencing) that perform protective functions by restricting progression in neurodegenerative diseases (Keren‐Shaul et al., 2017). TREM2 is a receptor for the activation of disease‐associated microglia and the TREM2 signaling pathway has been considered as a common microglial activation pathway in several neurodegenerative conditions and aging (Deczkowska et al., 2018; Krasemann et al., 2017). Compared with normal microglia the disease‐associated microglia progressively increase lipid metabolism and expression of phagocytic genes, and are specifically localized around AD plaques, thereby engulfing neurotoxic proteins and protecting against neurodegenerative diseases (Keren‐Shaul et al., 2017). However, recent discoveries using unbiased weighted co‐expression network analysis have shed light on another distinct pro‐inflammatory subpopulation of disease‐associated microglia in the context of AD (Rangaraju et al., 2018).

Currently, it is still unknown whether other disease‐associated microglia subsets in different neurological disorders exist or not, or indeed whether specific subtypes are common to several neurological disease states. However, we are optimistic that further studies employing comprehensive combined transcriptome, proteomic and metabolomic approaches will define a wider spectrum of microglia subsets in different neurological disorders and facilitate targeting microglia with unprecedented precision (Haimon et al., 2018; Rangaraju et al., 2018). Thus further studies are warranted to characterize the scope of intrinsic mechanisms of disease‐associated microglia during diverse disease conditions.

DEPLETING MICROGLIA IN DISEASES: THE FRIEND IN NEED MAY NOT ALWAYS BE DESIRABLE INDEED

A novel CX3CR1CreER R26Confetti multiple reporter system has been used to demonstrate that microglia can regulate their cell number by clonally forming a cluster at the site of local injury (Madore, Baufeld, & Butovsky, 2017; Tay et al., 2017). As described above, reactive microglia can lead to tissue damage, exacerbate deleterious effects and potentially contribute to neurodegeneration (Leyns & Holtzman, 2017). As it follows that microglia play a central role in many neurological disorders (Salter & Stevens, 2017; Wendeln et al., 2018), then microglia‐directed therapy, including specific microglia depletion strategies, can be regarded as a promising immunotherapy for neurological diseases (Du et al., 2017; Feng et al., 2017; Rice et al., 2015). In order to specifically deplete microglia in an injured CNS, many approaches including pharmacological inhibition (e.g. targeting the CSF‐R1 receptor with PLX5562) and genetic targeting have been developed (Waisman, Ginhoux, Greter, & Bruttger, 2015), and we have previously reviewed the outcomes of these approaches (Han, Harris, & Zhang, 2017; Lund, Pieber, & Harris, 2017).

In support of the hypothesis, microglial depletion has thus led to a broad range of positive and neuroprotective outcomes in distinct disease conditions by reducing neuroinflammation (Table 1): ameliorating EAE (Heppner et al., 2005; Lassmann & Bradl, 2017; Nissen, Thompson, West, & Tsirka, 2018); enhancing remyelination in the cuprizone demyelination model (Beckmann et al., 2018); attenuating neurological abnormalities and brain edema in two stroke mouse models (Li, Li, et al., 2017); reducing mRNA levels of proinflammatory cytokines such as IL‐1β and TNF‐α induced by peripheral lipopolysaccharide injection after microglial depletion (Xie et al., 2017); or acute binge ethanol withdrawal with little negative effects on behavioral functions (Walter & Crews, 2017). In one of our previous studies, we have indicated that cranial irradiation can cause transient accumulation of microglial cells followed by persistent inflammation and pronounced expression of IL‐1β and CCL2 in the hippocampus (Han et al., 2016). Indeed, neuroinflammation induced by activated resident microglia as well as infiltrating monocytes plays a pivotal role in hippocampal‐dependent severe cognitive dysfunction after both acute and long‐term irradiation (Feng et al., 2016) and microglial depletion can ameliorate these cranial radiation‐induced cognitive deficits (Acharya et al., 2016). Confirmed in another study, PLX5662‐mediated depletion can lead to protection from loss of dendritic spines, reduction of CD11b+Ly6G−Ly6Chi monocytes in the blood, inhibition of monocyte accumulation and ultimately prevention of radiation‐induced cognitive abnormalities (Feng et al., 2016). Furthermore, PLX5562 treatment can also alleviate two different forms of Charcot–Marie–Tooth disease by reducing neuropathic features, axonal damage and promoting hindlimb grip strength (Klein et al., 2015; Scherer, 2015). One more study showed that microglial depletion by PLX5562 treatment prevented the symptom of catatonia in structural myelin protein Cnp−/− mouse by reducing neuroinflammation and neurodegeneration (Janova et al., 2017).

Eliminating microglia in AD mice also provided beneficial outcomes including reduced neuronal loss, improvement of memory functions and partially preventing the progression of AD pathology, but had little effects on amyloid levels and plaque loads (Asai et al., 2015; Dagher et al., 2015; Olmos‐Alonso et al., 2016; Spangenberg et al., 2016). One recent study has indicated that microglial depletion in the CX3CR1CreER DTR transgenic mouse can lead to enlargement of Aβ plaques and may cause extensive neurite damage (Zhao, Hu, Tsai, Li, & Gan, 2017). However, early long‐term pharmacologically microglial depletion could finally inhibit plaque deposition and amyloid formation in the 5XFAD mouse model of AD, together with a relatively low level of soluble fibrillar oligomers in the brain (Sosna et al., 2018). Furthermore, the administration of GW2580 (tyrosine kinase inhibitor) orally can regulate inflammation of both the CNS and peripheral nervous systems in the ALS animal model, attenuating motoneuronal cell death, slowing disease progression and extending life expectancy (Martinez‐Muriana et al., 2016). However, this has not been confirmed in other studies using different approaches to deplete microglia (Gowing et al., 2008; Spiller et al., 2018). A beneficial outcome of microglial depletion is also evident in neuropathic pain by reducing the expression of pro‐inflammatory cytokines (Lee, Shi, Fan, West, & Zhang, 2018), which was also confirmed in another study (Wang, Mao, Wu, & Wang, 2018).

Despite this intensive research, microglia depletion as a treatment paradigm is still in its infancy. It is also of importance to note the differences of microglia activation in different types of disease processes. The findings mentioned above have to be interpreted with caution until we are sufficiently knowledgeable. On the basis of the above results, some critical issues need further investigation. For example, microglial elimination has been shown to exacerbate brain neurotoxicity in the contexts of brain ischemia, PD and coronavirus encephalitis (Jin et al., 2017; Szalay et al., 2016; Wheeler, Sariol, Meyerholz, & Perlman, 2018; Yang et al., 2018). Most microglial depletion studies have been performed using CSF‐1R inhibitors several weeks before inducing the animal disease models. However, it is more reasonable from a clinical perspective to deplete the activated microglial cells after disease onset. Furthermore, current research findings employing CSF‐1R kinase inhibitors (including PLX3397, PLX5562, GW2580, and BLZ945) might target multiple cell populations other than microglia (e.g. meningeal, perivascular and choroid plexus macrophages and microglial progenitor cells) (Yang et al., 2018). Cautious interpretation of pure microglial depletion effects using systemic delivery of current available CSF‐1R inhibitors is thus warranted. Indeed, recent studies have reported that CSF‐1R inhibition can deplete IBA+ macrophages in the kidney (Chalmers et al., 2017). In addition, CSF‐1R inhibition can robustly decline the actions of nerve‐associated macrophages in the periphery (Klein et al., 2015). However, several studies have identified some potential markers that are exclusively expressed in microglia including Tmem119, P2RY12, Siglec‐H and Sal1, permitting distinction of resident microglia from other myeloid cells (Bennett et al., 2016; Butovsky et al., 2014; Buttgereit et al., 2016; Konishi et al., 2017). These markers, together with the Cre/loxP technology, may make it possible to deplete microglia with exquisite precision in the near future.

Last but not the least, the potential side‐effects of microglial depletion is another crucial aspect to be considered. Under non‐sterile conditions the depletion of microglia might induce at least a transient immunodeficiency that could be harmful both with respect to CNS infection and also in disrupting normal CNS homeostatic functionality in unaffected brain areas. Indeed, the removal of immunomodulatory microglia producing and responding to TGF‐β could be expected to be a traumatic event in itself. The selective replacement of dysfunctional or aberrantly activated microglia in affected areas would thus be the most efficient approach. Most studies have indicated that no obvious behavioral consequences in adult mice following microglial depletion, despite extensive neuronal loss in the brain (Dagher et al., 2015; Elmore, Lee, West, & Green, 2015; Elmore et al., 2014; Rice et al., 2017). Microglial depletion in the adult wide‐type C57BL/6 mouse does not influence BDNF expression, the response of astrocytes and leukocyte infiltration in the experimental setting of PD (Yang et al., 2018). By contrast, neonatal microglial depletion during early life using pharmacological strategies can have a persistent impact on related motivated behavioral domains during adulthood (Nelson & Lenz, 2017). Furthermore, new tools to specifically deplete microglia by utilizing genetic approaches are in great demand. In a recent study, we have indicated that microglia can be efficiently depleted through the administration of tamoxifen in both CX3CR1CreER DTA and CX3CR1CreER DTR transgenic mice (Figure 2a) (Lund et al., 2018). This system thus allows for depletion of microglia at different disease stages by controlling the timing of tamoxifen provision.

MICROGLIAL REPOPULATION RESOLVES NEUROINFLAMMATION: NEW CELLS, NEW FRIENDS

Basic and clinical research demonstrates that suppressing the immune response by depleting autoreactive immune cells may re‐establish the immune balance (Wraith, 2017). Taking MS for example, monoclonal antibodies (including Rituximab and Ocrelizumab) that selectively target and deplete CD20+ B cells have been approved for the treatment of MS (Greenfield & Hauser, 2017; Hauser et al., 2017; Sabatino, Zamvil, & Hauser, 2018; Salzer et al., 2016). Our colleagues have demonstrated that relapsing–remitting MS patients with Rituximab as the initial treatment have better relapse control and tolerability in comparison with other disease‐modifying drugs (Granqvist et al., 2018; Spelman, Frisell, Piehl, & Hillert, 2017). Available MS treatments mainly resolve the peripheral inflammation but further specific and effective cell‐depletion therapies still represent a highly unmet medical need, especially in chronic disease states.

Due to the self‐renewal ability of microglia, following microglial depletion by pharmacological therapies or genetic targeting the empty CNS niche can be entirely repopulated within a relatively short period without serious side‐effects (Elmore et al., 2015; Han et al., 2017; Varvel et al., 2012). In a previous pioneering study, Elmore and colleagues indicated that rapid repopulation of microglial cells can be noted after administration of the selective CSF‐1R inhibitor PLX3397 (Elmore et al., 2014). They claimed that following cessation of PLX3397 treatment the newly repopulated cells did not arise from bone marrow‐derived cells, but instead from local nestin+ microglial progenitor cells in the brain parenchyma (Figure 2b) (Elmore et al., 2014). However, Bruttger et al demonstrated that following partial depletion (80%) in the CX3CR1CreER iDTR mouse, microglia proliferate by themselves rather than from nestin+ microglial progenitor cells to finally refill the niche (Figure 2d) (Bruttger et al., 2015; Jakel & Dimou, 2017). This mechanism has received further support (Askew et al., 2017) including using elegant fate‐mapping approaches, single‐cell RNA sequencing and parabiosis (Huang, Xu, Xiong, Sun, et al., 2018).

The recruitment of circulating precursors does not contribute to the resident microglial pool in the healthy CNS (Ajami, Bennett, Krieger, McNagny, & Rossi, 2011; Mildner et al., 2007). However, contradictory findings have been reported by using the CD11b‐HSVTK transgenic mouse in which circulating monocytes have the ability to potentially replace the adult CNS myeloid niche after microglial depletion (Figure 2c) (Varvel et al., 2012) and the newly engrafted peripheral cells have a unique functional phenotype compared with resident microglia (Cronk et al., 2018).

By contrast, two repopulating origins following microglial depletion in the retina have been described (Huang, Xu, Xiong, Qin, et al., 2018). One is the resident central‐emerging microglia in the optic nerve and the other is the extra‐retinal periphery‐emerging microglia from the ciliary body/iris (Huang, Xu, Xiong, Qin, et al., 2018). Two distinct resources including peripheral macrophages could also contribute to robust microglial regeneration independently of irradiation (Cronk et al., 2018). However, intrinsic regulatory mechanisms that mediate the replacement of microglia‐like cells after selective depletion are not yet fully understood.

One recent study provided novel evidence that CX3CR1 signaling may actively regulate microglial compensation in the retina since CX3CR1−/− deficient mice had significantly lower numbers of repopulated microglial during early recovery when compared to CX3CR1 signaling‐sufficient mice (Zhang et al., 2018). Furthermore, we have recently demonstrated that CNS repopulated monocytes required TGF‐β signaling to colonize the functional microglial niche following microglia depletion in the CX3CR1CreER DTA transgenic mouse model (Figure 2a) (Lund et al., 2018). Specific TGF‐β signaling deficiency on the new microglia‐like cells led to development of progressive motor disease similar to ALS‐like symptoms (Lund et al., 2018).

In this context, the next critical question is whether the newly engrafted microglia‐like cells including local hyperproliferation and/or bone marrow‐derived cells could completely adapt the embryonically seeded microglial phenotypes and functions. Even though they are numerically and morphologically different from embryonically seeded microglia, the newly repopulated cells can still perform the same general functions as resident microglia including constantly surveying the microenvironment and appropriately responding to the acute events (Varvel et al., 2012; Zhang et al., 2018). Additionally, embryonically seeded microglia and the newly repopulated cells may respond differently to environmental stimuli, as evidenced by two distinct cell types showing differential motilities in response to laser burn injury in vivo (Cronk et al., 2018). Using RNA sequencing it was determined that the gene profiles of fully repopulated microglia had been little influenced by administration of PLX5622 because no inflammatory related genes were up‐regulated or down‐regulated during depletion and repopulation processes (Huang, Xu, Xiong, Qin, et al., 2018). Consistent with this idea, Elmore and colleagues determined that repopulated microglia have relatively larger cell bodies than do resident microglia. These two types of microglial cells shared the same level of mRNA gene expression as well as similar responses to lipopolysaccharide stimulation (Elmore et al., 2015). Furthermore, mice with repopulated microglia did not exhibit any cognitive or behavioral abnormalities (Elmore et al., 2015).

More interestingly, the same research group further reported that repopulated microglia have the ability to largely resolve the pro‐inflammatory response and promote functional recovery after brain damage by replacing the active and highly swollen microglia with normal ramified microglia, downregulating the expression of reactive microglial markers and reducing the levels of inflammatory‐related genes (Rice et al., 2017). Furthermore, peripherally derived microglia‐like cells remained transcriptionally and functionally distinct from microglia arising through local proliferation (Cronk et al., 2018). Further evaluations are needed to confirm if overall brain function can be affected by mixed engrafted microglia‐like cells during diverse neurological disease models.

ENFORCED MICROGLIAL REPOPULATION: A NEW PROSPECT FOR FIXING A DYSFUNCTIONAL NICHE

So microglial depletion can lead to natural repopulation of the empty niche through either (a) hyperproliferation of remaining microglia, (b) stimulation of microglial precursors, or (c) infiltrating of monocytes from the circulation. An interesting aspect of myeloid cell repopulation with peripheral monocytes is that transcriptomic analyses reveal different outcomes in different tissues (Guilliams & Scott, 2017). Monocytes can thus replace Kupffer cells in the liver (Scott et al., 2016) and alveolar macrophages in the lung (van de Laar et al., 2016) with almost identical cellular phenotypes, while in the CNS bone marrow monocyte‐derived microglia only become microglia‐like cells, retaining more than 2,000 differentially expressed genes compared to resident microglia (Cronk et al., 2018). It is currently unknown why the CNS should differ in this respect to other tissues, but indicates that environmental cues must be tissue‐specific and of varied instructional consequence in different tissues (Bennett et al., 2018). It is also apparent that the repopulation process is tightly regulated, cells only occupying available tissue niches and the repopulation process (through either surviving microglia proliferation or monocyte infiltration) being halted through as yet undetermined mechanisms once the tissue is full. In certain studies an “overshoot” of repopulating cell numbers appears to be adjusted through selective loss of cells so that a homeostatic numerical occupancy is achieved. The important concept herein is that myeloid cell niches can be both efficiently depleted of resident cells and that repopulating cells can occupy the available niche with partial or total restoration of normal homeostatic functionality.

Microglial repopulation can arise from either bone marrow‐derived elements or local self‐renewal proliferation to replenish the empty niche in the CNS, which can be therapeutically targeted (Varvel et al., 2012; Waisman et al., 2015). It is also important to note that the therapeutic outcomes of the newly derived microglia can be fundamentally different during these two processes, as evidenced by recent data indicating that bone marrow‐derived microglia are functionally distinct from yolk sac‐derived microglia (Cronk et al., 2018). It follows that there might be specific advantages depending on the disease state. For example, if microglia are genetically dysfunctional, then self‐proliferation following depletion will not help. If the dysfunction extends to all myeloid cells (e.g. TREM2 in Nasu‐Hakola disease, ALS, and X‐linked adrenoleukodystrophy) then even repopulation by infiltrating monocytes will also not be beneficial. As monocyte‐derived repopulating cells would have a potentially different response to systemic stimuli compared to normal repopulating microglia, this is also an issue to contemplate. In contrast, it has been shown that bone marrow‐derived cells are much more efficient in clearing amyloid beta deposits compared to their endogenous counterparts (Kawanishi et al., 2018; Simard, Soulet, Gowing, Julien, & Rivest, 2006) and so monocyte repopulation would potentially be more efficient in AD.

A final scenario is enforced repopulation of pre‐defined myeloid cell through adoptive transfer. Natural microglia are excluded from this scenario, but blood‐derived monocytes or bone marrow‐derived macrophages, either unactivated, pre‐activated or genetically modified, have potential, as do stem cell‐derived myeloid cells. In order to successfully generate a sufficient source of renewable microglia‐like cells, several different protocols using cultured human inducible pluripotent stem cells (hiPSCs) have been recently established (Abud et al., 2017; Pocock & Piers, 2018). Specifically, hiPSCs are cultured with neuroglia differentiation media by supplement of CSF1 and IL‐34 to differentiate into Tmem119+/P2RY12+ microglia‐like cells that perform phagocytic functions (Muffat et al., 2016). Another well‐characterized method has been used to differentiate human and murine hiPSCs into microglia‐like cells through a hematopoietic progenitor‐like intermediate stage by adding defined factors and then co‐culturing with astrocytes (Pandya et al., 2017). A recently developed protocol for the derivation of microglia‐like cells from human monocytes could be the adoptive cell of most practical and functional relevance (Sellgren et al., 2017).

Considering that we have demonstrated the beneficial action of adoptively transferred immunomodulatory macrophages to prevent pathogenesis in settings of both Type 1 Diabetes (Parsa et al., 2012) and EAE (Zhang, Lund, Mia, Parsa, & Harris, 2014) and that other researchers have consequently successfully therapeutically employed our protocol in settings of spinal cord injury (Ma et al., 2015) and in wound healing (Riabov et al., 2017) then conceptually an initial transfer of immunomodulatory macrophages (either stimulated or gene‐modified) to halt the neuroinflammatory process could then be followed by transfer of microglia‐like cells. These approaches may provide a potential novel therapeutic angle for a wide array of neurological disorders and we currently actively explore this potential.

We thus propose that an immunotherapy protocol comprising total microglial ablation followed by the immediate enforced repopulation of the available niche through the adoptive transfer of myeloid cells could be considered as a means of replacing dysfunctional microglia in neurodegenerative states such as ALS and AD (Figure 3).

CONCLUDING REMARKS

Enforced microglia depletion and repopulation with fully differentiated cells, termed microglia‐replacement therapy, has great potential as an intervention in many neurological disease states. Optimization of timing between depletion and repopulation, long‐term effects on CNS homeostasis and long‐term therapeutic efficacy in preclinical models will provide a solid rationale for clinical translation.

CONFLICT OF INTEREST

The authors declare that there are no conflicts of interest.